PATRICK G ENRIGHT
CIK 1253886 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.05B
Companies
17
Total Filings
153
Lifetime Open-Market Net
-$89.38M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBIO | Director | 1,844,659 | $31.60 | $58.29M | $9.73M | 4 | 2026-06-17 |
| BIOA | Director | 1,310,589 | $22.17 | $29.06M | $7.20M | 3 | 2026-06-12 |
| VERA | Director | 3,602,475 | $33.27 | $119.87M | $32.53M | 11 | 2026-05-26 |
| MANE | Director | 2,407,752 | $111.99 | $269.64M | $18.27M | 1 | 2026-02-05 |
| JAZZ | Director | 21,379 | $258.48 | $5.53M | -$228.70M | 64 | 2026-01-08 |
| Aptinyx Inc. (APTX) Delisted | Director | 3,451,746 | $0.06 | $210.6K | $3.19M | 14 | 2022-05-31 |
| Sierra Oncology, Inc. (SRRA) Delisted | 10%+ Owner | 5,611 | $54.99 | $308.5K | $0 | 1 | 2022-04-29 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 195,935 | $2.57 | $503.6K | $12.60M | 1 | 2020-10-22 |
| COLL | Director | 0 | $36.30 | $0 | $1.92M | 11 | 2020-10-14 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,007,225 | $4.00 | $8.03M | $40.00M | 1 | 2020-07-28 |
| 89bio, Inc. (ETNB) Delisted | 10%+ Owner | 2,600,877 | $14.84 | $38.60M | $48.80M | 2 | 2020-07-14 |
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 279,902 | $0.00 | $28 | $29.98M | 1 | 2019-11-27 |
| Axonics, Inc. (AXNX) Delisted | 10%+ Owner | 2,933,333 | $70.98 | $208.21M | $24.00M | 1 | 2018-11-02 |
| KALA | 10%+ Owner | 823 | $0.67 | $555 | $12.90M | 1 | 2017-07-27 |
| CORT | Director | 5,993,653 | $93.91 | $562.86M | -$43.10M | 26 | 2017-03-20 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 7,467,694 | — | — | $10.45M | 3 | 2016-03-31 |
| ESPR | Director | 1,119,256 | $3.18 | $3.56M | -$69.15M | 6 | 2015-05-18 |
Recent Filings · Page 5 of 16
153 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-07-28 | Inozyme Pharma, Inc. (INZY) Delisted | Mixed | +11,277,516 | $40.00M | EDGAR |
| 2020-07-14 | 89bio, Inc. (ETNB) Delisted | Buy (P) | +436,360 | $12.00M | EDGAR |
| 2020-07-02 | Aptinyx Inc. (APTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-29 | COLL | Mixed | +7,840 | $0 | EDGAR |
| 2020-05-22 | Aptinyx Inc. (APTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-02 | Aptinyx Inc. (APTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-19 | COLL | Buy (P) | +125,000 | $1.42M | EDGAR |
| 2020-01-14 | Aptinyx Inc. (APTX) Delisted | Buy (P) | +261,667 | $785.0K | EDGAR |
| 2020-01-03 | Aptinyx Inc. (APTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-11-27 | Molecular Templates, Inc. (MTEM) Delisted | Buy (P) | +3,748,000 | $29.98M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.